Cholera toxin (CT), the causative agent of cholera, displays a pentavalent binding domain that targets the oligosaccharide of ganglioside GM1 (GM1os) on the periphery of human abdominal epithelial cells.
Introduction
Cholera still represents a serious health problem in areas of the developing world where there is a lack of clean water and proper sanitation. In 2012, the World Health Organization estimated that annually 3-5 million cholera cases occur that result in more than 100 000 deaths. 1 Although several treatments exist for cholera, 2 resistance development and mutations in the causative pathogen mean that efforts made to better understand the disease pathogenesis and develop new treatments are crucial. 3, 4 The symptoms of cholera are caused by cholera toxin (CT), which is produced by the Vibrio cholerae bacterium. CT is a member of the AB5 toxin family that contains a pentameric binding domain (CTB) for recognition and binding to cell surfaces. 5 The natural target ligand for CTB is the glycosphingolipid ganglioside GM1, on cellular membranes of the infected hosts' intestinal epithelial surface. CTB can bind five GM1 saccharide epitopes simultaneously with the terminal Gal-and the Neu5Ac carbohydrate units of the ganglioside as the major contributors to the binding. 6, 7 The adhesion of CTB to ganglioside GM1 on cell surfaces is the prerequisite for endocytosis of the toxic enzymatically active A subunit of CT, and the ensuing severe clinical symptoms. 8 One avenue in cholera research is to study the binding of CTB to GM1 and to develop CTB inhibitors that might prevent CT from binding the hosts' cell surface and thereby also the development of cholera. Here, we present the second of two examples of a pentavalent GM1os-based inhibitor for CTB, GM1os-calix [5] arene (1; Fig. 1 ). In the previous paper in this issue, we also reported on pentavalent inhibitors of CTB based on a GM1os-presenting corannulene scaffold. In the past, several studies have focused on the development of multivalent glycosylated inhibitors for CTB based on ganglioside GM1. 9 It is noteworthy that in none of these studies, inhibitors were investigated with a pentavalent structure that matches the pentavalent structure of CTB. On the other hand, pentavalent 10, 11 and cyclic peptides 12 have been described as CTB inhibitors, but those contained only the much simpler galactose epitope likely to get around the difficulty to obtain sufficient tailor-made GM1os. Therefore, also GM1 mimics have been used, e.g. Thompson and Schengrund described poly( propylene) imine dendrimers that present the Galβ1-3GalNAcβ1-4(Neu5Acα2-3)Galβ-epitope of GM1, 13 with IC 50 values for the tetravalent and octavalent dendrimers of 7 and 3 nM, respectively. Bernardi et al. published a series of GM1-mimics ( pseudo-GM1), in which the residues in the GM1os that are not essential for binding were replaced by a conformationally restricted cyclohexane-diol and the Neu5Ac-unit was substituted by various α-hydroxy acids. 14, 15 When attached to multivalent dendritic structures, 16 the relative inhibitory potency (RIP) values per mimic unit of the tetravalent and octavalent inhibitors were 111 and 55, respectively. Interestingly, when the same mimic was linked to a divalent calix [4] arene scaffold, 17 a 4000-fold enhancement in binding efficiency was achieved compared to the monovalent pseudo-GM1. These data suggested to us that the calixarene macrocycle, from which the binding inhibitors are projected, could be a promising multivalent scaffold [18] [19] [20] to design CTB inhibitors with improved efficiency. In collaboration with the group of Pieters, we previously published divalent, tetravalent, and octavalent dendritic structures decorated with GM1os. 21, 22 For the octavalent compound the unprecedentedly low IC 50 value of 50 pM was observed with an RIP of 17 500 per arm compared to its monovalent counterpart. However, its mismatched valency compared to CTB prompted us to investigate a pentavalent scaffold as core structure that when decorated with GM1os has the potential to form 1 : 1 inhibitor-CTB complexes. The current paper presents the convergent synthesis of the first, water-soluble, pentavalent CTB inhibitor (1), which was made by coupling five GM1os units to a calix [5] arene scaffold.
Results and discussion
We designed a 5-fold symmetric calix [5] arene as a pentavalent scaffold structure. This calix [5] arene (Fig. 1 ) presents small methoxy groups at the lower rim, which confer a high conformational flexibility to the macrocyclic structure. 23 The upper rim of the calixarene inhibitor is decorated with the GM1 pentasaccharide separated from the macrocyclic core by appropriate linkers. Fan and coworkers 12 have demonstrated that an optimal linker length is vital for the potency of a synthetic multivalent inhibitor. For the calix [5] arene, described here, a 31 atom-containing linker was chosen. This should allow the simultaneous interaction of the five GM1os units with the five B-subunits of a single toxin.
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The route towards our target (1) started with the synthesis of the pentavalent scaffold that began with the preparation of the known p-tert-butyl-calix [5] arene. 24 This product was converted into p-H-calix [5] arene 2 25 by following literature procedures. Next, penta-aldehyde 3 was obtained in 57% yield from 2 by exploiting the Duff formylation reaction. 26, 27 Compound 3 was subsequently methylated at the lower rim by using CH 3 I and K 2 CO 3 in acetonitrile affording the pentamethoxy-calix [5] arene 4 in 68% yield (Scheme 1). Oxidation of 4 with NaClO 2 and NH 2 SO 3 H produced the penta-carboxylic acid 5. The unsymmetrically substituted azido-penta-(ethyleneglycol)-amine 7 was synthesized from hexa-ethylene glycol by ditosylation, substitution to the diazide, and finally selective Staudinger reduction of one azide. 28, 29 Initial attempts to condense amine 7 with the carboxylic acids Scheme 1 Synthesis of the penta-azido-calix [5] arene (8) Organic & Biomolecular Chemistry Paper in 5 using HBTU resulted in difficult purification and low yields (∼20%) of 8. However, when this spacer (7) was attached to calix [5] arene 5 via penta-acyl chloride intermediate 6 it provided penta-azido-calix [5] arene 8 in a 44% yield. With the calix [5] arene (8) scaffold in hand we proceeded to the next stage, attaching five GM1 oligosaccharides. We chose the copper-catalyzed azide-alkyne cycloaddition (CuAAC) reaction to achieve this, which meant a GM1os derivative with a terminal alkyne was required. This C 11 -alkyne-terminated GM1os 9 (Scheme 2) was made via a chemo-enzymatic procedure previously reported by us, 30 which allowed the production of 9 on gram scale. Compound 9 was subsequently "clicked" to scaffold 8 under standard CuAAC conditions in H 2 O while exposed to microwave irradiation to successfully provide our crude target inhibitor 1. With our target pentavalent GM1os-calix [5] arene 1 in hand, in order to properly assess the role of the GM1os in inhibitor 1, we also set out to synthesize derivatives of 1 containing fragments of the GM1os to use for comparison in the biological assays. The first of these was penta-GM2os-calix [5] arene (11) that lacks the terminal galactose epitope compared to the GM1os. We synthesized 11 using the same CuAAC reaction conditions from scaffold 8 and a chemo-enzymatically produced alkyne-terminated C 11 -linked GM2os sugar (10) . With both our target 1 and its derivative 11 in hand as crude products, we investigated what purification method would be suitable for these large complex molecules. An initial purification by size exclusion chromatography (SEC) efficiently removed an excess of alkyne-terminated GM1os 9 and GM2os 10, respectively. However, the crude products both also contained a minor amount of tetravalent byproducts as could be clearly seen with mass spectrometry and their separation proved to be quite challenging. Initial attempts to separate these by aqueous HPLC GPC failed, but after extensive optimization, reversed phase HPLC purification proved the most successful for this final purification step (see experimental section for details). Fig. 2 shows a typical HPLC chromatogram for the separation of both the GM1os-and GM2os-calix [5] arenes. Despite attempts to improve the moderate resolution, the purification remained quite complicated because of long elution times (up to 40 minutes per run) and high affinity of the products with the column material. Collection of small fractions in a specific retention time window over multiple HPLC injections and subsequent lyophilization resulted indeed in pure pentavalent GM1os-and GM2os-calix [5] arenes (1 and 11) as shown by HR-MS and NMR analyses. The other impure fractions that also contained 1 or 11 were collected, pooled, lyophilized and re-injected to achieve optimal yields. Attempts were made to isolate the tetravalent byproducts, but insufficient amounts could be obtained for further analyses.
Besides the GM2os containing calixarene (11), we also prepared two further derivatives of 1 that contained fragments of GM1os, a pentavalent β-galactoside-(16) and β-lactoside-calix- [5] arene (17) (Scheme 3). These more simple carbohydrates enabled a modified synthesis procedure that circumvented the potentially challenging HPLC purification, as encountered for compounds 1 and 11. The coupling was also performed by employing the microwave-assisted CuAAC reaction on pentaazido-calixarene scaffold 8, but instead of using the deprotected carbohydrates, acetyl-protected galactoside 12, and lactoside 13 were reacted. The resulting products could now be purified by normal phase silica gel chromatograpy. The acetylprotected 14 and 15 were deprotected by employing standard Zemplén 31 conditions to obtain galactoside-calix [5] arene 16, and lactoside-calix [5] arene 17, respectively, which did not require further purification after work-up. Finally, in order to properly determine the multivalency effect of the interaction of 1 with CTB in our biological assays, we also synthesized the monovalent GM1os derivative 20 (Scheme 4). This was achieved by first in situ generation of the acyl chloride of commercially available 4-methoxybenzoic acid with oxalyl chloride and, subsequently, reacting this with amino-azide 7, yielding azide 19 in 20% over two steps. Again, by employing the microwave-assisted CuAAC reaction on alkyne-terminated 9 and azide 19, GM1os-monomer 20 was obtained in a reasonable yield (49%).
The inhibitory potency of the four pentavalent compounds (1, 11, 16, and 17) was determined by ELISA experiments. In the assays, the ability of 1, 11, 16 and 17 to inhibit the binding of HRP-labeled CTB was measured in competition with the natural ligand ganglioside GM1, which was adsorbed to the well surface of the ELISA plate. GM1os-calix [5] arene 1 showed a high inhibition potency, i.e., a very low IC 50 value of 450 pM ( Fig. 3 , Table 1 ). Comparing the IC 50 value (44 μM) of the monovalent control compound (20) to that of 1 revealed a 100-thousand increase in inhibitory potency, and an RIP of 20-thousand per arm. Pentavalent inhibitors based on a more rigid corannulene scaffold, which we also report in this issue, inhibited CTB in the nanomolar range. 32 Assay results for the GM2os-calix [5] arene 11 confirmed the importance of using GM1os. Lacking only the terminal galactose compared to 1, it produced an IC 50 of 9 μM, which is 20-thousand fold worse compared to 1. The galactose-terminated (16) and lactose-terminated (17) calix [5] arenes displayed a higher inhibition concentration than their solubility in the assay medium, and their IC 50 could therefore only be determined as being >1 mM (Table 1) .
Conclusions
In summary, we here report the synthesis and initial biological evaluation of the first known example of a pentavalent GM1os-based inhibitor of cholera toxin that matches the valency of the cholera toxin B-subunit. With an IC 50 of 450 pM, the pentavalent GM1os-calix [5] arene (1) also displays the highest relative inhibitory potency, 20-thousand per arm (compared to 20), documented thus far for CT inhibitors. We are currently using the here reported convergent synthetic route to further explore the structure-activity-relationship of 1 and improve its potency. Among other issues we are interested in investigating the effect of the length, rigidity and hydrophobicity of the used spacer and restricting the flexibility of the calix [5] arene scaffold to a fixed cone structure. 
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Experimental section
General experimental information
All moisture sensitive reactions were carried out under a nitrogen atmosphere, using previously oven-dried glassware. All dry solvents were prepared according to standard procedures, distilled before use and stored over 3 Å or 4 Å molecular sieves. 
GM1os-monomer (20)
Starting from compounds 19 and 9, following the same procedure as for compound 1, and using reversed phase column chromatography for the purification (gradient 
CTB5 inhibition assays
Each well of a 96-well microtiter plate was coated with a 100 μL native GM1 solution (1.3 μM in ethanol) after which the solvent was evaporated. Unattached GM1 was removed by washing with PBS (3 × 450 μL), the remaining free binding sites were blocked by incubation with 100 μL of a 1% (w/v) BSA solution in PBS for 30 min at 37°C. Detection limits were determined by placing a CT-horseradish peroxidase conjugate (CT-HRP), without inhibitor, on the plate, which gives the highest response, and the lowest response was determined by the optical density of the blank, i.e. the native GM1-coated well with all components except the inhibitor and the toxin. These two values represent the minimum and the maximum values of optical density, 0% and 100% of binding of the CT to the GM1-coating of the wells. Subsequently, the wells were washed with PBS (3 × 450 μL). In separate vials, a logarithmic serial dilution was performed that started from 2.0 mM of 150 μL saccharide-calixarenes in 0.1% BSA and 0.05% Tween-20 in PBS. Next, each vial was mixed and incubated with 150 μL of a 50 ng mL −1 CTB-HRP solution in the same buffer. This gave an initial inhibitor concentration of 1.0 mM. In the case of potent inhibitors, based on the logarithmic experiments, a more accurate, serial dilution of a factor two was performed around the expected IC 50 -values. The inhibitor-toxin mixtures were incubated at room temperature for 2 h and then transferred to the coated wells. After 30 min of incubation at room temperature, unbound CTB-HRP-calixarene complexes were removed from the wells by washing with 0.1% BSA, 0.05% Tween-20 in PBS (3 × 500 μL). 100 μL of a freshly prepared OPD solution (25 mg OPD·2HCl, 7.5 mL 0.1 M citric acid, 7.5 mL 0.1 M sodium citrate and 6 μL of a 30% H 2 O 2 solution, pH was adjusted to 6.0 with NaOH) was added to each well and allowed to react with HRP in the absence of light, at room temperature, for 15 minutes. The oxidation reaction was quenched by addition of 50 μL 1 M H 2 SO 4 . Within 5 min, the absorbance was measured at 490 nm.
